HNB
NAGE

Huntington National Bank’s Niagen Bioscience NAGE Stock Holding History

Huntington National Bank’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,917
Closed -$5K – 2456
2022
Q2 		$5K Buy
+2,917
New +$5.7K ﹤0.01% 1749

Other funds holding NAGE

TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Huntington National Bank's NAGE Position: Q3 2022 in Review

Huntington National Bank sold out of Niagen Bioscience (NAGE) in Q3 2022, closing a stake of 2,917 shares — an estimated $5K sold.

Huntington National Bank first reported a position in NAGE in Q2 2022 and held it in 1 quarter. The position peaked at $5K in Q2 2022. 62 funds tracked by Wall St. Rank hold NAGE as of Q3 2022.

  • Huntington National Bank reported no remaining Niagen Bioscience position as of Q3 2022 after selling out during the quarter.
  • Huntington National Bank sold 2,917 Niagen Bioscience shares in Q3 2022, an estimated $5K.
  • Huntington National Bank first reported a position in Niagen Bioscience in Q2 2022 and held it in 1 quarter.
  • Huntington National Bank's Niagen Bioscience position peaked at $5K in Q2 2022.
  • 62 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2022.

Based on Huntington National Bank's 13F filing for Q3 2022, filed 7 Nov 2022.